THe beta-Blocker Heart Attack Trial: studies of platelets and factor VIII

Related Experiment Video

Updated: Aug 8, 2026

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

D Green, E C Rossi, O Haring

    Thrombosis Research
    |October 15, 1982
    PubMed

    Insights

    Propranolol, a beta blocker, was studied in heart attack patients. While it didn't affect certain blood factors, it significantly reduced circulating platelet aggregates, suggesting an impact on platelet reactivity.

    Area of Science:

    • Cardiology
    • Hematology
    • Pharmacology

    Background:

    • Platelet activation and aggregation are critical in myocardial infarction pathogenesis.
    • Beta-blockers are widely used post-myocardial infarction, but their direct effects on platelet function require further elucidation.

    Purpose of the Study:

    • To investigate the in vivo effects of propranolol on platelet function and Factor VIII parameters in patients post-myocardial infarction.
    • To assess if propranolol influences platelet-collagen affinity, factor VIII coagulant activity, factor VIII related antigen, or ristocetin cofactor activity.

    Main Methods:

    • Serial blood samples were collected from 16 patients in the Beta Blocker Heart Attack Trial.
    • Eight patients received placebo, while eight were treated with propranolol (40-320 mg/day) for 6-31 months.
    • Platelet function tests (collagen affinity, aggregates) and Factor VIII assays were performed.

    Main Results:

    • No significant differences were observed in platelet-collagen affinity, factor VIII coagulant activity, factor VIII related antigen, or ristocetin cofactor activity between groups.
    • Circulating platelet aggregates, initially elevated in both groups, significantly decreased in patients treated with propranolol (p < 0.05).

    Conclusions:

    • Customary doses of propranolol demonstrate an in vivo effect on platelet reactivity, specifically reducing circulating platelet aggregates.
    • These findings suggest a potential mechanism beyond beta-adrenergic blockade by which propranolol may influence thrombotic processes in cardiovascular disease.

    More Related Videos

    Ferric Chloride-induced Murine Thrombosis Models10:37

    Ferric Chloride-induced Murine Thrombosis Models

    Published on: September 5, 2016

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    Related Concept Videos

    Heart Failure Drugs: &#946;-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Formation of the Platelet Plug01:22

    Formation of the Platelet Plug

    The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
    As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
    Clot Retraction and Fibrinolysis01:16

    Clot Retraction and Fibrinolysis

    After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...